vs
Side-by-side financial comparison of Astera Labs, Inc. (ALAB) and Nutex Health, Inc. (NUTX). Click either name above to swap in a different company.
Astera Labs, Inc. is the larger business by last-quarter revenue ($270.6M vs $151.7M, roughly 1.8× Nutex Health, Inc.). Astera Labs, Inc. runs the higher net margin — 16.6% vs 7.8%, a 8.8% gap on every dollar of revenue. On growth, Astera Labs, Inc. posted the faster year-over-year revenue change (91.8% vs -41.1%). Astera Labs, Inc. produced more free cash flow last quarter ($76.6M vs $69.0M). Over the past eight quarters, Astera Labs, Inc.'s revenue compounded faster (103.6% CAGR vs 50.0%).
Astera Labs, Inc. is an American fabless semiconductor manufacturer and artificial intelligence company. The company specializes in designing high-speed connectivity solutions for data centers and AI infrastructure. The company has been listed on the Nasdaq since March 2024.
Nutex Health Inc. is an American for-profit health care company and operator of healthcare facilities headquartered in Houston, Texas.
ALAB vs NUTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.6M | $151.7M |
| Net Profit | $45.0M | $11.8M |
| Gross Margin | 75.6% | 30.4% |
| Operating Margin | 24.7% | 20.4% |
| Net Margin | 16.6% | 7.8% |
| Revenue YoY | 91.8% | -41.1% |
| Net Profit YoY | 82.0% | -80.8% |
| EPS (diluted) | $0.25 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.6M | $151.7M | ||
| Q3 25 | $230.6M | $267.8M | ||
| Q2 25 | $191.9M | $244.0M | ||
| Q1 25 | $159.4M | $211.8M | ||
| Q4 24 | $141.1M | $257.6M | ||
| Q3 24 | $113.1M | $78.8M | ||
| Q2 24 | $76.8M | $76.1M | ||
| Q1 24 | $65.3M | $67.5M |
| Q4 25 | $45.0M | $11.8M | ||
| Q3 25 | $91.1M | $55.4M | ||
| Q2 25 | $51.2M | $-17.7M | ||
| Q1 25 | $31.8M | $21.2M | ||
| Q4 24 | $24.7M | $61.6M | ||
| Q3 24 | $-7.6M | $-8.8M | ||
| Q2 24 | $-7.5M | $-364.0K | ||
| Q1 24 | $-93.0M | $-364.0K |
| Q4 25 | 75.6% | 30.4% | ||
| Q3 25 | 76.2% | 57.8% | ||
| Q2 25 | 75.8% | 51.2% | ||
| Q1 25 | 74.9% | 55.9% | ||
| Q4 24 | 74.0% | 55.0% | ||
| Q3 24 | 77.7% | 27.8% | ||
| Q2 24 | 77.9% | 29.7% | ||
| Q1 24 | 77.4% | 15.1% |
| Q4 25 | 24.7% | 20.4% | ||
| Q3 25 | 24.0% | 48.7% | ||
| Q2 25 | 20.7% | 13.8% | ||
| Q1 25 | 7.1% | 38.1% | ||
| Q4 24 | 0.1% | 44.4% | ||
| Q3 24 | -7.9% | 12.3% | ||
| Q2 24 | -31.7% | 7.0% | ||
| Q1 24 | -127.1% | 2.1% |
| Q4 25 | 16.6% | 7.8% | ||
| Q3 25 | 39.5% | 20.7% | ||
| Q2 25 | 26.7% | -7.3% | ||
| Q1 25 | 20.0% | 10.0% | ||
| Q4 24 | 17.5% | 23.9% | ||
| Q3 24 | -6.7% | -11.2% | ||
| Q2 24 | -9.8% | -0.5% | ||
| Q1 24 | -142.5% | -0.5% |
| Q4 25 | $0.25 | $2.34 | ||
| Q3 25 | $0.50 | $7.76 | ||
| Q2 25 | $0.29 | $-2.95 | ||
| Q1 25 | $0.18 | $3.33 | ||
| Q4 24 | $1.23 | $11.56 | ||
| Q3 24 | $-0.05 | $-1.72 | ||
| Q2 24 | $-0.05 | $-0.07 | ||
| Q1 24 | $-1.77 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $185.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $329.4M |
| Total Assets | $1.5B | $918.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $185.6M | ||
| Q3 25 | $140.4M | $166.0M | ||
| Q2 25 | $162.3M | $96.7M | ||
| Q1 25 | $86.4M | $84.7M | ||
| Q4 24 | $79.6M | $40.6M | ||
| Q3 24 | $126.1M | $46.9M | ||
| Q2 24 | $421.1M | $40.8M | ||
| Q1 24 | $696.1M | $30.0M |
| Q4 25 | $1.4B | $329.4M | ||
| Q3 25 | $1.3B | $317.2M | ||
| Q2 25 | $1.1B | $235.3M | ||
| Q1 25 | $1.0B | $176.9M | ||
| Q4 24 | $964.8M | $132.4M | ||
| Q3 24 | $889.6M | $60.4M | ||
| Q2 24 | $845.3M | $62.7M | ||
| Q1 24 | $808.8M | $63.0M |
| Q4 25 | $1.5B | $918.5M | ||
| Q3 25 | $1.4B | $964.5M | ||
| Q2 25 | $1.3B | $841.0M | ||
| Q1 25 | $1.1B | $761.9M | ||
| Q4 24 | $1.1B | $655.3M | ||
| Q3 24 | $983.1M | $438.5M | ||
| Q2 24 | $915.5M | $422.4M | ||
| Q1 24 | $864.9M | $404.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $95.3M | $70.4M |
| Free Cash FlowOCF − Capex | $76.6M | $69.0M |
| FCF MarginFCF / Revenue | 28.3% | 45.5% |
| Capex IntensityCapex / Revenue | 6.9% | 0.9% |
| Cash ConversionOCF / Net Profit | 2.12× | 5.95× |
| TTM Free Cash FlowTrailing 4 quarters | $281.8M | $245.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $70.4M | ||
| Q3 25 | $78.2M | $99.5M | ||
| Q2 25 | $135.4M | $27.3M | ||
| Q1 25 | $10.5M | $51.0M | ||
| Q4 24 | $39.7M | $54.0K | ||
| Q3 24 | $63.5M | $6.8M | ||
| Q2 24 | $29.8M | $13.3M | ||
| Q1 24 | $3.7M | $3.1M |
| Q4 25 | $76.6M | $69.0M | ||
| Q3 25 | $65.9M | $99.2M | ||
| Q2 25 | $133.3M | $26.5M | ||
| Q1 25 | $6.0M | $50.9M | ||
| Q4 24 | $24.3M | $-341.0K | ||
| Q3 24 | $46.8M | $6.2M | ||
| Q2 24 | $28.5M | $12.7M | ||
| Q1 24 | $228.0K | $2.3M |
| Q4 25 | 28.3% | 45.5% | ||
| Q3 25 | 28.6% | 37.0% | ||
| Q2 25 | 69.5% | 10.9% | ||
| Q1 25 | 3.7% | 24.0% | ||
| Q4 24 | 17.2% | -0.1% | ||
| Q3 24 | 41.4% | 7.8% | ||
| Q2 24 | 37.1% | 16.7% | ||
| Q1 24 | 0.3% | 3.4% |
| Q4 25 | 6.9% | 0.9% | ||
| Q3 25 | 5.3% | 0.1% | ||
| Q2 25 | 1.1% | 0.3% | ||
| Q1 25 | 2.8% | 0.0% | ||
| Q4 24 | 10.9% | 0.2% | ||
| Q3 24 | 14.8% | 0.8% | ||
| Q2 24 | 1.7% | 0.7% | ||
| Q1 24 | 5.2% | 1.1% |
| Q4 25 | 2.12× | 5.95× | ||
| Q3 25 | 0.86× | 1.80× | ||
| Q2 25 | 2.64× | — | ||
| Q1 25 | 0.33× | 2.40× | ||
| Q4 24 | 1.61× | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALAB
Segment breakdown not available.
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
